Optimal antagonism of the renin-angiotensin-aldosterone system: Do we need dual or triple therapy?

Drugs

Volumn 70, Issue 10, 2010, Pages 1215-1230

  Werner, Christian ^a   Pöss, Janine ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

ACE inhibitors; Aldosterone antagonists; Aliskiren; Angiotensin receptor antagonists; Atherosclerosis; Eplerenone; Hypertension; Myocardial infarction; Spironolactone; Stroke; therapeutic use; treatment

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANRENOIC ACID; CAPTOPRIL; CYCLOOXYGENASE 2 INHIBITOR; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; VALSARTAN; MINERALOCORTICOID ANTAGONIST;

ADD ON THERAPY; ADRENAL DISEASE; ALBUMINURIA; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DEATH; DIABETIC NEPHROPATHY; DIET; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HEART VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; MEDICAL PRACTICE; MICROALBUMINURIA; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SELECTION; PREMATURITY; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SAFETY; SECONDARY PREVENTION; SIDE EFFECT; STROKE; SYMPTOM; UNSPECIFIED SIDE EFFECT; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG EFFECTS; KIDNEY DISEASES;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY DISEASES; MODELS, BIOLOGICAL; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; ANGIOTENSIN RECEPTOR ANTAGONISTS; MINERALOCORTICOID RECEPTOR ANTAGONISTS;

EID: 77953839811     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11537910-000000000-00000     Document Type: Note

References (82)

1. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121 (4 Pt 1): 1244-1263
2. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984; 2 (3): 277-284
3. Nickenig G, Harrison DG. The AT(1)-type angiotensin re-ceptor in oxidative stress and atherogenesis. Part I: oxidative stress and atherogenesis. Circulation 2002; 105 (3): 393-396 (Pubitemid 34106191)
4. Nickenig G, Harrison DG. The AT(1)-type angiotensin re-ceptor in oxidative stress and atherogenesis. Part II: AT(1) receptor regulation. Circulation 2002; 105 (4): 530-536 (Pubitemid 34262669)
5. van de Wal RM, van Veldhuisen DJ, van Gilst WH, et al. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? Eur Heart J 2005 Nov; 26 (22): 2361-2367
6. Steckelings UM, Rettig R, Unger T. Angiotensin in the kidney: a key to understanding hypertension? Cell Metab 2007; 5 (1): 7-8
7. Unger T, Stoppelhaar M. Rationale for double renin-angiotensin- aldosterone system blockade. Am J Cardiol 2007; 100 (3A): 25J-31 8.
8. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004 Aug 5; 351 (6): 585-592
9. Cohen SA, Jondeau G, Beauvais F, et al. Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure. Eur J Heart Fail 2004 Jun; 6 (4): 463-466
10. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007; 20 (5): 587-597
11. Menard J, Azizi M. The difficult conception, birth and de-livery of a renin inhibitor: controversies around aliskiren. J Hypertens 2007; 25 (9): 1775-1782
12. Schefe JH, Menk M, Reinemund J, et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006; 99 (12): 1355-1366
13. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28 (12): 1462-1536
14. Doulton TW, He FJ, Macgregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45 (5): 880-886
15. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369 (9557): 201-207
16. Perticone F, Ceravolo R, Pujia A, et al. Prognostic signifi-cance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104 (2): 191-196
17. Schmieder RE. Endothelial dysfunction: how can one in-tervene at the beginning of the cardiovascular continuum? J Hypertens Suppl 2006; 24 (2): S31-5
18. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephro-pathy in patients with type 2 diabetes. N Engl J Med 2001; 345 (12): 870-878
19. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106 (6): 672-678
20. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369 (9568): 1208-1219
21. Dell'Italia LJ, Meng QC, Balcells E, et al. Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. Am J Physiol 1995 Dec; 269 (6 Pt 2): H2065-73
22. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342 (3): 145-153
23. Lonn E, Shaikholeslami R, Yi Q, et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial. J Am Coll Cardiol 2004; 43 (12): 2200-2206
24. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359 (9311): 995-1003 (Pubitemid 34286536)
25. Hoshida S, Kato J, Nishino M, et al. Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation 2001; 103 (5): 630-633
26. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15): 1547-1559
27. Yusuf S, Teo K, Anderson C, et al. Effects of the angioten-sin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008 Sep 27; 372 (9644): 1174-1183
28. Verdecchia P, Sleight P, Mancia G, et al., ONTARGET/TRANSCEND Investigators. Effects of telmisartan, ra-mipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009 Oct 6; 120 (14): 1380-1389
29. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused up-date incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009 Apr 14; 53 (15): e1-90
30. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure). Developed in collaboration with the American College ofChest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112 (12): e154-235
31. Arnold JM, Yusuf S, Young J, et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003; 107 (9): 1284-1290 (Pubitemid 36314412)
32. Fox KM. Efficacy of perindopril in reduction of cardio-vascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782-788
33. Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351 (20): 2058-2068
34. Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in sub-groups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006; 24 (11): 2163-2168
35. Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369 (9571): 1431-1439
36. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 2002; 360 (9335): 752-760
37. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987 Jun 4; 316 (23): 1429-1435
38. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD Investigators. N Engl J Med 1991; 325 (5): 293-302
39. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of capto-pril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial: the SAVE Investigators. N Engl J Med 1992; 327 (10): 669-677
40. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure: the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342 (8875): 821-828
41. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandola-pril in patients with left ventricular dysfunction after myocardial infarction: Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333 (25): 1670-1676
42. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355 (9215): 1582-1587
43. van de Wal RM, Plokker HW, Lok DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006; 106 (3): 367-372
44. Rouleau JL, Moye LA, de Champlain J, et al. Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol 1991 Nov 18; 68 (14): 80D-6
45. Mann JF, Schmieder RE, McQueen M, et al. Renal out-comes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008 Aug 16; 372 (9638): 547-553
46. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008 Jan 1; 148 (1): 30-48
47. Berl T. Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2009 Mar; 10 (1): 1-8
48. Fried LF, Duckworth W, Zhang JH, et al. Design of com-bination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009 Feb; 4 (2): 361-368
49. Group TCTS. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316 (23): 1429-1435
50. Granger CB, McMurray JJ, Yusuf S, et al. Effects of can-desartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362 (9386): 772-776 (Pubitemid 37093917)
51. Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2004; 110 (15): 2180-2183
52. McMurray J, Solomon S, Pieper K, et al. The effect of val-sartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol 2006; 47 (4): 726-733
53. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362 (9386): 767-771 (Pubitemid 37093916)
54. Solomon SD, Skali H, Anavekar NS, et al. Changes in ven-tricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 2005; 111 (25): 3411-3419
55. Califf RM, LokhnyginaY, Velazquez EJ, et al. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). Am J Cardiol 2009 Jul 15; 104 (2): 151-157
56. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349 (20): 1893-1906
57. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100 (10): 1056-1064
58. Krum H, Carson P, Farsang C, et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004 Dec; 6 (7): 937-945
59. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and toler-ability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 2008 Apr; 14 (3): 181-188
60. Hoppe UC. Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists? Clin Res Cardiol 2007; 96 (4): 196-198
61. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357 (22): 2248-2261
62. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 Apr 3; 348 (14): 1309-1321
63. Chapman N, Dobson J, Wilson S, et al. Effect of spiro-nolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007 Apr; 49 (4): 839-845
64. Pitt B, Zannad F, Remme WJ, et al. The effect of spir-onolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 Sep 2; 341 (10): 709-717
65. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hy-perkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004 Aug 5; 351 (6): 543-551
66. Adamopoulos C, Ahmed A, Fay R, et al. Timing of epler-enone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail 2009 Nov; 11 (11): 1099-1105
67. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009 Feb; 30 (4): 469-477
68. Pitt B, Bakris G, Ruilope LM, et al. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myo-cardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008 Oct 14; 118 (16): 1643-1650
69. Pitt B. Aldosterone blockade in patients with heart failure and a reduced left ventricular ejection fraction. Eur Heart J 2009 Feb; 30 (4): 387-388
70. Mak GJ, Ledwidge MT, Watson CJ, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009 Oct 27; 54 (18): 1674-1682
71. Montezano AC, Touyz RM. Networking between systemic angiotensin II and cardiac mineralocorticoid receptors. Hypertension 2008 Dec; 52 (6): 1016-1018
72. A comparison of outcomes in patients in New York Heart Association (NYHA) class II heart failure when treated with eplerenone or placebo in addition to standard heart failure medicines (EMPHASIS-HF) [ClinicalTrials.gov identifier NCT00232180]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2009 Nov 30]
73. Aldosterone antagonist therapy for adults with heart failure and preserved systolic function (TOPCAT) [Clinical Trials.gov identifier NCT00094302]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2009 Nov 30]
74. Lee HY, Oh BH. Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program. Expert Rev Cardiovasc Ther 2009 Mar; 7 (3): 251-257
75. Sever PS, Gradman AH, Azizi M. Managing cardiovascular and renal risk: the potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst 2009 Jun; 10 (2): 65-76
76. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008 Jun 5; 358 (23): 2433-2446
77. McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008 May; 1 (1): 17-24
78. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct Renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009 Feb 3; 119 (4): 530-537
79. Jacobshagen C, Westermann D, Holubarsch C, et al. Hot-line update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more. Clin Res Cardiol 2010 Jun; 99 (6): 337-344 Epub 2010 Apr 16
80. Dusing R, Sellers F. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr Med Res Opin 2009 Sep; 25 (9): 2287-2301
81. Chrysant SG, Murray AV, Hoppe UC, et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin 2008 Apr; 24 (4): 1039-1047
82. McAlpine HM, Cobbe SM. Neuroendocrine changes inacute myocardial infarction. Am J Med 1988 Mar 11; 84 (3A): 61-66